Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BHVN Stock Forecast 2026-2027
$10.01
Current Price
$1.51B
Market Cap
Buy 14
Hold 5
Sell 0
Wall St Analyst Ratings
Distance to BHVN Price Targets
+399.5%
To High Target of $50.00
+109.8%
To Median Target of $21.00
-10.1%
To Low Target of $9.00
BHVN Price Momentum
+9.2%
1 Week Change
+5.0%
1 Month Change
-50.9%
1 Year Change
-11.3%
Year-to-Date Change
-58.4%
From 52W High of $24.06
+33.8%
From 52W Low of $7.48
📊 TOP ANALYST CALLS
Did BHVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Biohaven is one of their latest high-conviction picks.
Latest BHVN Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, BHVN has a bullish consensus with a median price target of $21.00 (ranging from $9.00 to $50.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $10.01, the median forecast implies a 109.8% upside. This outlook is supported by 14 Buy, 5 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Marc Goodman at Leerink Partners, projecting a 399.5% upside. Conversely, the most conservative target is provided by Leonid Timashev at RBC Capital, suggesting a 10.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BHVN Analyst Ratings
14
Buy
5
Hold
0
Sell
BHVN Price Target Range
Low
$9.00
Average
$21.00
High
$50.00
Current: $10.01
Latest BHVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BHVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2026 | Citigroup | Samantha Semenkow | Buy | Maintains | $17.00 |
| Mar 11, 2026 | TD Cowen | Tyler Van Buren | Buy | Maintains | $30.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Douglas Tsao | Neutral | Maintains | $10.00 |
| Mar 3, 2026 | RBC Capital | Leonid Timashev | Outperform | Maintains | $23.00 |
| Jan 21, 2026 | RBC Capital | Leonid Timashev | Outperform | Upgrade | $22.00 |
| Jan 6, 2026 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $21.00 |
| Dec 26, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Reiterates | $11.00 |
| Dec 3, 2025 | HC Wainwright & Co. | Douglas Tsao | Neutral | Downgrade | $11.00 |
| Nov 26, 2025 | UBS | Ashwani Verma | Neutral | Downgrade | $11.00 |
| Nov 20, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $15.00 |
| Nov 18, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $26.00 |
| Nov 18, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $16.00 |
| Nov 13, 2025 | Citigroup | Samantha Semenkow | Buy | Maintains | $14.00 |
| Nov 6, 2025 | RBC Capital | Leonid Timashev | Sector Perform | Maintains | $9.00 |
| Nov 6, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $16.00 |
| Nov 6, 2025 | Bernstein | William Pickering | Market Perform | Downgrade | $9.00 |
| Nov 5, 2025 | TD Cowen | Tyler Van Buren | Buy | Maintains | $15.00 |
| Nov 5, 2025 | William Blair | Myles Minter | Market Perform | Downgrade | $N/A |
| Sep 17, 2025 | Citigroup | Samantha Semenkow | Buy | Initiates | $28.00 |
| Sep 16, 2025 | UBS | Ashwani Verma | Buy | Maintains | $26.00 |
Biohaven Ltd. (BHVN) Competitors
The following stocks are similar to Biohaven based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BHVN
Biohaven Pharmaceuticals
mkt cap
1.38B
Biohaven Ltd. (BHVN) Financial Data
Valuation Metrics
Market Cap
$1.51B
Enterprise Value
$1.53B
P/E Ratio
N/A
PEG Ratio
-5.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+21.2%
Current Ratio
3.2x
Debt/Equity
546.6x
ROE
-310.8%
ROA
-83.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Biohaven Ltd. (BHVN) Business Model
About Biohaven Ltd.
What They Do
Develops therapies for neurological diseases.
Business Model
Biohaven Ltd. operates as a clinical-stage biopharmaceutical company focused on creating innovative drugs for neurological and neuropsychiatric conditions. The company generates revenue through the development of therapies that address unmet medical needs, particularly in migraine relief and neurodegenerative diseases, utilizing advanced research platforms such as CGRP receptor antagonists and glutamate modulation.
Additional Information
Headquartered in New Haven, Connecticut, Biohaven Ltd. plays a significant role in the biotechnology sector, with a promising pipeline of therapeutic candidates that could have a substantial impact on healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
274
CEO
Dr. Vladimir Coric M.D.
Country
United States
IPO Year
2017
Website
www.biohaven.comBiohaven Ltd. (BHVN) Latest News & Analysis
Latest News
Why Biohaven Stock Crushed it on Monday
3 days ago
Quick Summary
A pundit has recommended the stock as a buy, anticipating that its price will more than double.
Why It Matters
A stock labeled as a buy with expectations to double in price signals potential growth, attracting investor interest and possibly driving up demand and share prices.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Biohaven Ltd. downgraded to Hold after FDA's rejection of troriluzole for Spinocerebellar Ataxia. Focus shifts to three late-stage programs, including taldefgrobep alfa for obesity, with phase 2 data expected in 2026.
Why It Matters
The downgrade signals reduced confidence in Biohaven's prospects after FDA setbacks, impacting stock performance. Focus on late-stage programs may influence future growth and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sarissa Capital Management acquired 513,184 shares of Biohaven in Q4, increasing its position value by $5.79 million at quarter-end.
Why It Matters
Sarissa Capital's significant share acquisition in Biohaven signals confidence in the company's future, potentially impacting stock performance and attracting attention from other investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
DAFNA Capital Management acquired 720,000 shares of Biohaven for approximately $8.92 million in Q4, with the position's value increasing by $7.25 million by quarter-end.
Why It Matters
DAFNA Capital's significant investment in Biohaven and subsequent value increase signal confidence in the company's prospects, potentially influencing market sentiment and stock performance.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
A Phase 2 study of taldefgrobep alfa for obesity is fully enrolled, with topline data anticipated in 2H 2026. It targets fat and muscle via the myostatin-activin pathway.
Why It Matters
The full enrollment of the Phase 2 study for taldefgrobep alfa signals potential advancements in obesity treatment, which could impact market valuations and competitive positioning in the healthcare sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
1 month ago
Quick Summary
The company is focusing on three late-stage clinical programs, including BHV-1300 for Graves' disease, which showed up to 87% reduction in disease-causing antibodies and normalized thyroid hormones.
Why It Matters
The advancements in BHV-1300 and other clinical programs signal potential breakthroughs in treating immunological diseases, epilepsy, and obesity, which could drive stock value and market interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BHVN Stock
What is Biohaven Ltd.'s (BHVN) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, Biohaven Ltd. (BHVN) has a median price target of $21.00. The highest price target is $50.00 and the lowest is $9.00.
Is BHVN stock a good investment in 2026?
According to current analyst ratings, BHVN has 14 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BHVN stock?
Wall Street analysts predict BHVN stock could reach $21.00 in the next 12 months. This represents a 109.8% increase from the current price of $10.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biohaven Ltd.'s business model?
Biohaven Ltd. operates as a clinical-stage biopharmaceutical company focused on creating innovative drugs for neurological and neuropsychiatric conditions. The company generates revenue through the development of therapies that address unmet medical needs, particularly in migraine relief and neurodegenerative diseases, utilizing advanced research platforms such as CGRP receptor antagonists and glutamate modulation.
What is the highest forecasted price for BHVN Biohaven Ltd.?
The highest price target for BHVN is $50.00 from Marc Goodman at Leerink Partners, which represents a 399.5% increase from the current price of $10.01.
What is the lowest forecasted price for BHVN Biohaven Ltd.?
The lowest price target for BHVN is $9.00 from Leonid Timashev at RBC Capital, which represents a -10.1% decrease from the current price of $10.01.
What is the overall BHVN consensus from analysts for Biohaven Ltd.?
The overall analyst consensus for BHVN is bullish. Out of 26 Wall Street analysts, 14 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are BHVN stock price projections?
Stock price projections, including those for Biohaven Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 2:14 AM UTC